Compare DFH & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFH | SLBT |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Homebuilding | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2025 |
| Metric | DFH | SLBT |
|---|---|---|
| Price | $13.80 | $3.15 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 534.4K | 39.9K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $36.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $2.51 |
| 52 Week High | $31.10 | $6.25 |
| Indicator | DFH | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 53.94 |
| Support Level | $12.35 | $2.52 |
| Resistance Level | $16.47 | $3.40 |
| Average True Range (ATR) | 0.67 | 0.19 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 12.15 | 71.85 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.